
Kovai Medical Center and Hospital Q4 FY26 Results: PAT Rs 59.7 Cr
Updated: 25 May 2026 • 4:50 pm
Posted by:

Kovai Medical Center and Hospital Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 59.7 crore for the quarter ended March 31, 2026, up 8.9% YoY compared to Rs 54.8 crore in Q4 FY25. Revenue from operations was Rs 485 crore, up 14.1% YoY. Results are on a Consolidated basis. Kovai Medical Center and Hospital is a Hospitals and Healthcare company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Kovai Medical Center and Hospital Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | Rs 485 crore | Rs 425 crore | +14.1% |
| Net Profit | 59.7 | 54.8 | +8.9% |
| Basis | Consolidated | ||
Note: Q4 FY26 profit rises 9% to Rs 59.7 crore as revenue jumps 14% to Rs 485 crore. Verify from BSE/NSE audited filings before investment decisions.
Kovai Medical Center and Hospital Q4 FY26 Performance Analysis
The Kovai Medical Center and Hospital Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The company delivered stable results in line with sector conditions. Kovai Medical Center and Hospital operates in the Hospitals and Healthcare sector, which benefits from India’s GDP growth above 6.5% and domestic demand conditions in FY26.
Revenue of Rs 485 crore was up 14.1% YoY. Stable revenue reflects consistent business conditions.
Screen the best stocks on the Univest Screener.
Key Factors Driving Kovai Medical Center and Hospital Q4 FY26 Results
Revenue and Business Execution
Revenue of Rs 485 crore in Kovai Medical Center and Hospital Q4 FY26 was up 14.1% YoY. Double-digit revenue growth reflects strong demand conditions and market expansion. The January to March quarter is the fiscal year-end quarter, characterised by strong execution cycles and year-end activity.
Profitability and Margin Trends
The Kovai Medical Center and Hospital Q4 FY26 PAT of Rs 59.7 crore up 8.9% YoY. Stable profitability reflects consistent operational delivery.
India Macro Environment Q4 FY26
India’s macro environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The RBI’s accommodative stance supported credit and demand conditions. The Hospitals and Healthcare sector benefited from these structural tailwinds during the quarter.
FY27 Outlook
Following Kovai Medical Center and Hospital Q4 FY26 results, management guidance on FY27 revenue growth, margin trajectory, and capital allocation will be key investor watchpoints. Consistent growth delivery and margin improvement remain the strategic priorities.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Kovai Medical Center and Hospital Q4 FY26 net profit?
Ans. Kovai Medical Center and Hospital Q4 FY26 PAT of Rs 59.7 crore, up 8.9% YoY from Rs 54.8 crore in Q4 FY25. Results declared May 22, 2026, on a Consolidated basis. Verify from BSE/NSE audited filings.
What is Kovai Medical Center and Hospital Q4 FY26 revenue?
Ans. Kovai Medical Center and Hospital Q4 FY26 revenue was Rs 485 crore, up 14.1% YoY. Verify complete financials from BSE/NSE.
When were Kovai Medical Center and Hospital Q4 FY26 results declared?
Ans. Kovai Medical Center and Hospital Q4 FY26 results were declared on May 22, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.
Is Kovai Medical Center and Hospital a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
Recent Articles

Syncom Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
22 June 2026

Aspinwall Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
22 June 2026

Vesuvius India Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
22 June 2026

BL Agro Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
22 June 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Syncom Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Aspinwall Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Vesuvius India Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
BL Agro Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Tirumal Chem Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Popular this week
Syncom Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Aspinwall Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Vesuvius India Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
BL Agro Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
Tirumal Chem Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





